Clinical Scorecard: FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
At a Glance
| Category | Detail |
|---|---|
| Condition | Sanfilippo Syndrome Type A |
| Key Mechanisms | AAV9 gene therapy delivering a functional copy of SGSH to restore sulfamidase production. |
| Target Population | Pediatric patients with preserved neurodevelopmental function. |
| Care Setting | Clinical treatment for neurological manifestations of mucopolysaccharidosis type IIIA. |
Key Highlights
- Fayuvi (rebisufligene etisparvovec-hopf) is the first FDA-approved treatment for Sanfilippo syndrome type A.
- The therapy aims to restore enzyme function and reduce heparan sulfate accumulation.
- In treated patients, a mean increase of 16 points in cognitive scores was observed compared to a decline in untreated patients.
- Common adverse reactions include elevated liver enzymes in 85% of patients.
- Patients require corticosteroid treatment and monitoring post-infusion.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of MPS IIIA based on clinical and genetic criteria.
Management
- Administer Fayuvi as a one-time intravenous infusion.
Monitoring & Follow-up
- Monitor liver enzymes and other potential adverse reactions post-treatment.
Risks
- Potential risks include thrombocytopenia, infusion reactions, thrombotic microangiopathy, and malignancy from vector DNA integration.
Patient & Prescribing Data
Children diagnosed with Sanfilippo syndrome type A and preserved neurodevelopmental function.
Requires corticosteroid treatment before and after infusion.
Clinical Best Practices
- Conduct thorough monitoring of liver function and neurological status post-treatment.
- Utilize external natural history cohorts for comparative analysis due to the rarity of the disease.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
